FMC Corporation 2025 Q1 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. FMC Corporation is a global agricultural sciences company operating in a single segment, developing crop protection chemicals (insecticides, herbicides, fungicides) and plant health products. The company completed the divestiture of its Global Specialty Solutions (GSS) business in November 2024.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $791.4 million | $918.0 million |
| Gross Margin | $316.7 million (40.0%) | $339.7 million (37.0%) |
| Net Income (Loss) Attributable to FMC | $(15.5) million | $(2.7) million |
| Diluted EPS | $(0.12) | $(0.02) |
| Adjusted EBITDA (Non-GAAP) | $119.7 million | $160.6 million |
| Cash from Operating Activities (Continuing) | $(545.0) million | $(142.9) million |
| Total Debt | $4,003.5 million | $4,335.7 million |
| Cash and Cash Equivalents | $315.3 million | $357.3 million |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 14% year-over-year, driven by a 9% price decline (over half attributed to "cost-plus" contract adjustments for diamide partners), a 1% volume decrease, and a 4% foreign currency headwind.
- Regional Performance: North America sales fell 28% and Asia fell 24% due to channel destocking and trade dynamics. Latin America was the only region with growth, up 10%.
- Profitability: While gross margin dollars decreased, the gross margin percentage improved to 40% from 37% due to lower raw material costs and fixed cost absorption. However, net loss widened significantly due to lower sales, increased SG&A and R&D spending, and a higher tax provision.
- Cash Flow: Operating cash flow turned significantly negative ($545.0 million outflow) compared to the prior year, primarily due to a $452.0 million reduction in advance payments from customers (seasonal timing) and a $164.9 million increase in inventory.
- Debt: Total debt increased to $4.0 billion, largely due to a rise in commercial paper borrowings ($694.8 million) to fund working capital needs.
Guidance, Outlook, and Risks
- 2025 Revenue Outlook: Expected to range from $4.15 billion to $4.35 billion (essentially flat vs. 2024). Excluding the GSS divestiture, this represents a 3% increase.
- 2025 Adjusted EBITDA: Forecast between $870 million and $950 million. This range includes estimated incremental tariff costs of $15 million to $20 million.
- 2025 Adjusted EPS: Expected to range from $3.26 to $3.70 per diluted share.
- Share Repurchases: The company suspended share repurchases under its public program until December 31, 2027, per a credit agreement amendment. $825 million remains available under the authorization.
- Risks: Key risks include trade policy changes and tariffs, supply chain disruptions (particularly for raw materials sourced from China and India), and foreign currency volatility. The company noted potential impacts from OECD Pillar Two tax legislation.
Investor Verification Checklist
- Working Capital Seasonality: Verify the impact of the $452 million drawdown in customer advance payments on Q1 cash flow and whether this is a recurring seasonal pattern.
- Price Adjustments: Confirm the duration and scope of the "cost-plus" contract adjustments affecting diamide partners and their impact on future pricing power.
- Inventory Build: Assess the rationale for the $165 million increase in inventory against the backdrop of channel destocking in North America and Asia.
- Tax Provision Volatility: Review the drivers of the 275.5% effective tax rate in Q1 2025, specifically the impact of foreign currency and the mix of earnings.
- Restructuring Progress: Monitor the execution of "Project Focus," which has incurred $13.6 million in Q1 2025 charges, with total expected charges ranging from $375 million to $425 million.